Hardman Johnston Global Advisors LLC Lowers Holdings in Edwards Lifesciences Co. (NYSE:EW)

Hardman Johnston Global Advisors LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 298,086 shares of the medical research company’s stock after selling 7,170 shares during the period. Hardman Johnston Global Advisors LLC owned approximately 0.05% of Edwards Lifesciences worth $22,067,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Alpha Financial Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $693,000. International Assets Investment Management LLC boosted its position in shares of Edwards Lifesciences by 10,990.6% during the 3rd quarter. International Assets Investment Management LLC now owns 163,919 shares of the medical research company’s stock worth $10,817,000 after purchasing an additional 162,441 shares in the last quarter. Mount Yale Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 41.0% in the 3rd quarter. Mount Yale Investment Advisors LLC now owns 8,401 shares of the medical research company’s stock worth $554,000 after buying an additional 2,441 shares in the last quarter. Forsta AP Fonden boosted its position in shares of Edwards Lifesciences by 12.0% in the 3rd quarter. Forsta AP Fonden now owns 134,000 shares of the medical research company’s stock worth $8,843,000 after buying an additional 14,400 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Edwards Lifesciences by 3.8% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 1,747,168 shares of the medical research company’s stock worth $115,668,000 after buying an additional 64,613 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $73.25 on Monday. The stock’s fifty day simple moving average is $72.85 and its 200 day simple moving average is $70.06. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $43.20 billion, a price-to-earnings ratio of 10.51, a P/E/G ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on EW shares. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Truist Financial reissued a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Finally, Barclays upped their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.95.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,489 shares of company stock valued at $2,002,829. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.